RxDoctor Payments Data

Leslie Cooper, MD

Cardiovascular Disease · Jacksonville, FLNPI 1801872056

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $91,593 of the $91,928 with a category attached, or 99.6%. E.r. Squibb & Sons, L.L.C. accounts for 76.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $31,175 and has fallen 76.5% since, to $7,324 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$91,928in general payments, 2019–2025

Across 31 payments — averaging $2965.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$70K
  • Modernatx, Inc.$19K
  • CSL Behring$2K
  • Kiniksa Pharmaceuticals, Ltd.$1K
  • Shockwave Medical, Inc$124
  • AstraZeneca$20

What the payments were for

  • Consulting fees$91,593100%
  • Travel & lodging$950%
  • Food & beverage$2400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,928 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Medicare billing

Part B allowed, 2024
$75,488
Medicare patients
411
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$117,616
EntrestoSacubitril/Valsartan76$89,101
JardianceEmpagliflozin66$86,251
FarxigaDapagliflozin Propanediol83$63,299
Praluent PenAlirocumab15$13,013
Metoprolol Succinate68$1,139
Atorvastatin Calcium57$711
Potassium Chloride14$675
Eplerenone17$615
Spironolactone72$512
Ezetimibe21$447
Amlodipine Besylate27$352
Carvedilol36$252
Rosuvastatin Calcium24$238
Candesartan Cilexetil14$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$20$63,29983 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →